MS 2025 21 - 25 October 2025

Impact of semaglutide 2.4 mg and oral semaglutide 25 mg on QoL in women with obesity: A post hoc analysis of the STEP and OASIS programs by menopausal status

Authors :

Maria Daniela Hurtado Andrade^1,2; Rebecca Dunsmoor-Su^3,4; Emilia Huvinen⁵; Naveen Rathor⁶; Nanette Santoro⁷; Lauren Wilson⁸; Sushmita Yaganti⁸; Santiago Palacios⁹

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Obesity

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Impact of semaglutide 2.4 mg and oral semaglutide 25 mg on QoL in women with obesity: A post hoc analysis of the STEP and OASIS programs by menopausal status